Abstract
Sepsis remains a major cause of death in critically ill patients admitted to the intensive care unit (ICU) [1]–[2]. Infections increase the all-cause mortality during ICU admission from 12.1% in non-infected patients to 43.9% in infected patients [3]. Timely and effective antimicrobial treatment has crucial importance for prognosis. Delayed correct antimicrobial treatment substantially increases mortality [4]. The Surviving Sepsis Campaign has optimized multifactorial sepsis treatment in an evidence-based manner, to the benefit of critically ill patients with sepsis [5].
on behalf of the Procalcitonin and Survival Study (PASS) Group (see Appendix)
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C (2003) Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med 3:2742–2751
Alberti C, Brun-Buisson C, Burchardi H, et al (2002) Epidemiology of sepsis and infection in ICU patients from an international multicentre cohort study. Intensive Care Med 28:108–121
Alberti C, Brun-Buisson C, Goodman SV, et al (2003) European Sepsis Group. Influence of systemic inflammatory response syndrome and sepsis on outcome of critically ill infected patients. Am J Respir Crit Care Med 168:77–84
Kollef MH, Sherman G, Ward S, Fraser VJ (1999) Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462–474
Dellinger RP, Carlet JM, Masur H, et al (2004) Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med 32:858–873
Weglohner W, Struck J, Fischer-Schulz C, et al (2001) Isolation and characterization of serum procalcitonin from patients with sepsis. Peptides 22:2099–2103
Birnbaum RS, Mahoney WC, Burns DM, O’Neil JA, Miller RE, Roos BA (1984) Identification of procalcitonin in a rat medullary thyroid carcinoma cell line. J Biol Chem 259:2870–2874
Becker KL, Nylen ES, White JC, Muller B, Snider RH Jr (2004) Clinical review 167: Procalcitonin and the calcitonin gene family of peptides in inflammation, infection, and sepsis: a journey from calcitonin back to its precursors. J Clin Endocrinol Metab 89:1512–1525
Chesney RW, McCarron DM, Haddad JG, et al (1983) Pathogenic mechanisms of the hypocalcemia of the staphylococcal toxic-shock syndrome. J Lab Clin Med 101:576–585
Muller B, White JC, Nylen ES, Snider RH, Becker KL, Habener JF (2001) Ubiquitous expression of the calcitonin-i gene in multiple tissues in response to sepsis. J Clin Endocrinol Metab 86:396–404
Christ-Crain M, Morgenthaler NG, Struck J, Harbarth S, Bergmann A, Muller B (2005) Midregional pro-adrenomedullin as a prognostic marker in sepsis: an observational study. Crit Care 9:R816–824
Burns DM, Forstrom JM, Friday KE, Howard GA, Roos BA (1989) Procalcitonin’s amino-terminal cleavage peptide is a bone-cell mitogen. Proc Natl Acad Sci USA 86:9519–9523
Monneret G, Arpin M, Venet F, et al (2003) Calcitonin gene related peptide and N-procalcitonin modulate CD11b upregulation in lipopolysaccharide activated monocytes and neutrophils. Intensive Care Med 29:923–928
Wiedermann FJ, Kaneider N, Egger P, et al (2002) Migration of human monocytes in response to procalcitonin. Crit Care Med 30:1112–1117
Hoffmann G, Czechowski M, Schloesser M, Schobersberger W (2002) Procalcitonin amplifies inducible nitric oxide synthase gene expression and nitric oxide production in vascular smooth muscle cells. Crit Care Med 30:2091–2095
Whang KT, Vath SD, Becker KL, et al (2000) Procalcitonin and proinflammatory cytokine interactions in sepsis. Shock 14:73–78
Nylen ES, Whang KT, Snider RH Jr, Steinwald PM, White JC, Becker KL (1998) Mortality is increased by procalcitonin and decreased by an antiserum reactive to procalcitonin in experimental sepsis. Crit Care Med 26:1001–1006
Wagner KE, Martinez JM, Vath SD, et al (2002) Early immunoneutralization of calcitonin precursors attenuates the adverse physiologic response to sepsis in pigs. Crit Care Med 30:2313–2321
Jensen JU, Heslet L, Jensen TH, Espersen K, Steffensen P, Tvede M (2006) Procalcitonin increase in early identification of critically ill patients at high risk of mortality. Crit Care Med 34:2596–2602
Meisner M, Lohs T, Huettemann E, Schmidt J, Hueller M, Reinhart K (2001) The plasma elimination rate and urinary secretion of procalcitonin in patients with normal and impaired renal function. Eur J Anaesthesiol 18:79–87
Level C, Chauveau P, Delmas Y, et al (2001) Procalcitonin: a new marker of inflammation in haemodialysis patients? Nephrol Dial Transplant 16:980–986
Sitter T, Schmidt M, Schneider S, Schiffl H (2002) Differential diagnosis of bacterial infection and inflammatory response in kidney diseases using procalcitonin. J Nephrol 15:297–301
Level C, Chauveau P, Guisset O, et al (2003) Mass transfer, clearance and plasma concentration of procalcitonin during continuous venovenous hemofiltration in patients with septic shock and acute oliguric renal failure. Crit Care 7:R160–166
Lindberg M, Hole A, Johnsen H, et al (2002) Reference intervals for procalcitonin and C-reactive protein after major abdominal surgery. Scand J Clin Lab Invest 62:189–194
Reith HB, Mittelkotter U, Debus ES, Kussner C, Thiede A (1998) Procalcitonin in early detection of postoperative complications. Dig Surg 15:260–265
Meisner M, Tschaikowsky K, Hutzler A, Schick C, Schuttler J (1998) Postoperative plasma concentrations of procalcitonin after different types of surgery. Intensive Care Med 24:680–684
Redl H, Schlag G, Togel E, Assicot M, Bohuon C (2000) Procalcitonin release patterns in a baboon model of trauma and sepsis: relationship to cytokines and neopterin. Crit Care Med 28:3659–3663
Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al (2004) Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 363:600–607
Christ-Crain M, Stolz D, Bingisser R? et al (2006) Procalcitonin guidance of antibiotic therapy in community-acquired pneumonia: A randomized trial. Am J Respir Crit Care Med 174:84–93
Bone RC, Sibbald WJ, Sprung CL (1992) The ACCP-SCCM consensus conference on sepsis and organ failure. Chest 101:1481–1483
Simon L, Gauvin F, Amre DK, Saint-Louis P, Lacroix J (2004) Serum procalcitonin and Creactive protein levels as markers of bacterial infection: a systematic review and meta-analysis. Clin Infect Dis 39:206–217
Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D (1970) Catheterization of the heart in man with use of a flow-directed balloon-tipped catheter. N Engl J Med 283:447–451
Spackman TN (1994) A theoretical evaluation of cost-effectiveness of pulmonary artery catheters in patients undergoing coronary artery surgery. J Cardiothorac Vasc Anesth 8:570–576
Connors AF Jr, Speroff T, Dawson NV, et al (1996) The effectiveness of right heart catheterization in the initial care of critically ill patients. SUPPORT Investigators. JAMA 276:889–897
Wheeler AP, Bernard GR, Thompson BT, et al (2006) Pulmonary-artery versus central venous catheter to guide treatment of acute lung injury. N Engl J Med 354:2213–2224
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Science + Business Media Inc.
About this paper
Cite this paper
Jensen, J.U., Løken, J., Mohr, T. (2007). Procalcitonin: Nice to Know, Need to know, or Needs Further Research?. In: Vincent, JL. (eds) Intensive Care Medicine. Springer, New York, NY. https://doi.org/10.1007/978-0-387-49518-7_2
Download citation
DOI: https://doi.org/10.1007/978-0-387-49518-7_2
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-49517-0
Online ISBN: 978-0-387-49518-7
eBook Packages: MedicineMedicine (R0)